
Iptakalim Hydrochloride
CAS No. 642407-63-4
Iptakalim Hydrochloride ( —— )
产品货号. M27888 CAS No. 642407-63-4
Iptakalim 是一种亲脂性对氨基化合物,是一种新型 ATP 敏感钾通道 (KATP) 开放剂,也是一种含有 α4β2 的烟碱乙酰胆碱受体 (nAChR) 拮抗剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥389 | 有现货 |
![]() ![]() |
10MG | ¥599 | 有现货 |
![]() ![]() |
25MG | ¥1199 | 有现货 |
![]() ![]() |
50MG | ¥1952 | 有现货 |
![]() ![]() |
100MG | ¥2940 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Iptakalim Hydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Iptakalim 是一种亲脂性对氨基化合物,是一种新型 ATP 敏感钾通道 (KATP) 开放剂,也是一种含有 α4β2 的烟碱乙酰胆碱受体 (nAChR) 拮抗剂。
-
产品描述Iptakalim, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist. Iptakalim is also a K(ir) 6.1/SUR2B activator that can attenuate hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection.
-
体外实验Iptakalim (Ipt) hydrochloride has been shown to reverse pulmonary resistance vascular remodeling, inhibit proliferation of pulmonary arterial smooth muscle cells (PASMCs) and airway smooth muscle cells (ASMCs), as well as protect PAECs from pathological stimulation.Iptakalim has an inhibitory effect on [Ca2+]cyt increase and the proliferation of pulmonary arterial SMCs induced by endothelin-1 through activation of KATP channels. Iptakalim (10 μM, 10 min) pretreatment of pulmonary arterial SMCs significantly prevents ransient ncrease of [Ca2+]cyt elicited by endothelin-1.Iptakalim at he concentrations of 0.1, 1, and 10 AM lowered[3H]thymidine incorporation by 19.75±4.60% (n=10), 41.20±9.49% (n=10), and 54.74±10.11% (n=10), respectively, compared with that of cells treated only with endothelin-1.
-
体内实验Iptakalim (10-60 mg/kg) attenuates nicotine-evoked conditioned responding. Iptakalim also attenuates chamber activity in these nicotine test sessions..Iptakalim (60 mg/kg) pretreatment significantly reduced activity (LSD comparisons).. Animal Model:Thirty male Sprague-Dawley rats weighing 275-299 grams.Dosage:0, 10, 30, or 60 mg/kg.Administration:IP, 10 min before the start of a 4-min test session.Result:Decreased chamber activity.Dipper entries following pretreatment with 30 and 60 mg/kg Iptakalim were significantly lower than with 0 (saline) or 10 mg/kg iptakalim pretreatment (Tukey HSD tests).
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点Potassium Channel
-
受体Aldose reductase
-
研究领域——
-
适应症——
化学信息
-
CAS Number642407-63-4
-
分子量179.73
-
分子式C9H22ClN
-
纯度>98% (HPLC)
-
溶解度In Vitro:?H2O : 25 mg/mL (139.10 mM)
-
SMILESCl.CC(C)NC(C)(C)C(C)C
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Simard-Duquesne N, et al. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Metabolism. 1985 Oct;34(10):885-92.
产品手册




关联产品
-
ICA
ICA 是一种 SK 通道抑制剂,具有抗利什曼活性 (IC50:2.1 μM)。
-
Rabeprazole
Rabeprazole (LY307640) 是一种二代质子泵抑制剂 (pump inhibitor, PPI),不可逆地抑制胃 H+/K+-ATPase。Rabeprazole 诱导细胞凋亡 (apoptosis)。Rabeprazole 也抑制尿苷核苷核糖水解酶 (UNH) ,IC50 为 0.3 μM。Rabeprazole 可用于胃溃疡和胃食管反流的研究。
-
VU590
VU590 是一种有效的和中等选择性的肾外髓质钾 ROMK (Kir1.1) 抑制剂,IC50 为290 nM。VU590 对 Kir7.1 也具有抑制作用,IC50 为 8 μM。VU590 VU590 不是肾脏中 ROMK 功能的良好探针。